---

Top Highlights for November 2013:  (Please click on read more to see details)

 

1. Indian cos. sign PE deals worth $8.9 billion in Jan-Oct'13, out of which pharma and healthcare accounted 26% 

2. Global buyout fund KKR to acquire a 35% stake India’s Gland Pharma for $210.56 Mn Read more

3. Italian pharma giant Menarini eyeing Indian brands in the range of $80-85 Mn Read more

4. Pfizer & Wyeth’s Indian subsidiaries merge to tap Indian pharma industry which is expected to hit $55 billion in annual sales by 2020 Read more

5. With an investment of $17.5 Mn, India & UK to collaborate for joint research projects in Farmed Animal health and Disease Read more

6. India's Cipla acquired an additional 14.5% stake in Quality Chemical Industries Limited, Uganda for $15 Mn, adding up to total 51.05% stake post acquisition 

7. Piramal India, Ci-Co Korea in partnership & exclusive licensing agreement for Alzheimer drug 

8. India ahead of US, China as best investment zone - E&Y global survey Read more

9. India has emerged as a global leader in vaccine market with 33.33% share of the total market Read more

Aagami - updates (Please click on link to view details)

 

Two new client wins: 

 

•  I: Innate Immune Drug Development Company based in Ireland. This company is focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases. The client has appointed Aagami to help them find partner(s) in India for Licensing and/or Co-development with large potential in pancreatic cancer, Gastric cancer, MDS and Myocardial Infarction/STEMI.

 

•   II : Euopean Biotech Company - The client has an exciting and revolutionary technology to improve biopharmaceuticals. Owing to Aagami's deal making experience, expertise and extensive network in India, the client appointed Aagami to support them with their Technology Out-Licensing needs.